Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AbbVie : VENCLEXTA Receives FDA Full Approval for Acute Myeloid Leukemia

10/19/2020 | 10:22am EST

NORTH CHICAGO - AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

The approval is supported by data from the Phase 3 VIALE-A (M15-656) and VIALE-C (M16-043) studies and updated data from the Phase 1b M14-358 and the Phase 1/2 M14-387 studies. The FDA previously granted accelerated approval to VENCLEXTA for this indication in 2018.5

'AML is a complex and challenging disease with generally low survival rates. This approval is significant because data from our VIALE-A trial has shown that newly-diagnosed patients, who cannot undergo intensive chemotherapy, lived longer when treated with VENCLEXTA plus azacitidine than those treated with azacitidine alone,' said Mohamed Zaki, M.D., Ph.D., vice president and global head of oncology development, AbbVie. 'This trial also provides physicians more information for managing patients - from treatment initiation, to assessing response and management post disease remission.'

Positive overall survival (OS) data seen at an interim analysis of the VIALE-A trial led to an early submission supporting the FDA approval of VENCLEXTA in AML. The trial showed patients on the active regimen of VENCLEXTA plus azacitidine achieved a 34% reduction in the risk of death compared to azacitidine in combination with placebo (Hazard Ratio [HR]=0.66 [95% CI: 0.52-0.85], p

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ABBVIE INC.
12/02ABBVIE : Working With Frontier Medicines to Develop Therapeutics
DJ
12/02ABBVIE : and Frontier Medicines Establish Global Partnership to Discover and Dev..
PR
12/02FRONTIER MEDICINES : and AbbVie Establish Global Partnership to Discover and Dev..
PR
12/01ABBVIE : to Host Virtual Immunology Strategic Update
PR
11/25ABBVIE : to Present at the Evercore ISI Conference and Piper Sandler Healthcare ..
AQ
11/24ABBVIE : to Present at the Evercore ISI Conference and Piper Sandler Healthcare ..
PR
11/19ABBVIE : Announces Expiration and Final Results of Registered Exchange Offers
AQ
11/18ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/18ABBVIE : Announces Expiration and Final Results of Registered Exchange Offers
PR
11/18Berkshire's bet a bright spot in gloomy year for Big Pharma stocks
RE
More news
Financials (USD)
Sales 2020 45 620 M - -
Net income 2020 12 365 M - -
Net Debt 2020 74 496 M - -
P/E ratio 2020 25,6x
Yield 2020 4,51%
Capitalization 185 B 185 B -
EV / Sales 2020 5,69x
EV / Sales 2021 4,61x
Nbr of Employees 47 000
Free-Float 98,5%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 111,64 $
Last Close Price 104,74 $
Spread / Highest target 21,3%
Spread / Average Target 6,58%
Spread / Lowest Target -7,39%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.18.30%184 916
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071